- Home
- ABUS vs CGEM Comparison
ABUS vs CGEM Comparison
Compare ABUS & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABUS
- CGEM
- Stock Information
- Founded
- ABUS N/A
- CGEM 2016
- Country
- ABUS United States
- CGEM United States
- Employees
- ABUS N/A
- CGEM N/A
- Industry
- ABUS Biotechnology: Pharmaceutical Preparations
- CGEM Biotechnology: Pharmaceutical Preparations
- Sector
- ABUS Health Care
- CGEM Health Care
- Exchange
- ABUS Nasdaq
- CGEM Nasdaq
- Market Cap
- ABUS 617.3M
- CGEM 506.1M
- IPO Year
- ABUS N/A
- CGEM 2021
- Fundamental
- Price
- ABUS $3.51
- CGEM $7.82
- Analyst Decision
- ABUS Strong Buy
- CGEM Strong Buy
- Analyst Count
- ABUS 4
- CGEM 8
- Target Price
- ABUS $5.50
- CGEM $32.86
- AVG Volume (30 Days)
- ABUS 1.0M
- CGEM 415.4K
- Earning Date
- ABUS 03-27-2025
- CGEM 05-14-2025
- Dividend Yield
- ABUS N/A
- CGEM N/A
- EPS Growth
- ABUS N/A
- CGEM N/A
- EPS
- ABUS N/A
- CGEM N/A
- Revenue
- ABUS $6,171,000.00
- CGEM N/A
- Revenue This Year
- ABUS N/A
- CGEM N/A
- Revenue Next Year
- ABUS $61.99
- CGEM $278.37
- P/E Ratio
- ABUS N/A
- CGEM N/A
- Revenue Growth
- ABUS N/A
- CGEM N/A
- 52 Week Low
- ABUS $2.30
- CGEM $7.27
- 52 Week High
- ABUS $4.72
- CGEM $30.19
- Technical
- Relative Strength Index (RSI)
- ABUS 58.89
- CGEM 37.99
- Support Level
- ABUS $3.20
- CGEM $7.27
- Resistance Level
- ABUS $3.45
- CGEM $9.16
- Average True Range (ATR)
- ABUS 0.14
- CGEM 0.43
- MACD
- ABUS 0.03
- CGEM -0.05
- Stochastic Oscillator
- ABUS 78.65
- CGEM 29.10
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.